We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock
DCPH

Delisted

DCPH was delisted on the 10th of June, 2024.

Back to rankings

122 hedge funds and large institutions have $1.2B invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 49 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

370% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 10

158% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 19

130% more capital invested

Capital invested by funds: $522M → $1.2B (+$680M)

44% more funds holding

Funds holding: 85 → 122 (+37)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

39% less call options, than puts

Call options by funds: $5.44M | Put options by funds: $8.87M

Holders
122
Holders Change
+37
Holders Change %
+43.53%
% of All Funds
2.68%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
47
Increased
49
Reduced
19
Closed
10
Calls
$5.44M
Puts
$8.87M
Net Calls
-$3.42M
Net Calls Change
+$16.3M

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$75.7M
2
AllianceBernstein
AllianceBernstein
Tennessee
+$39M
3
Millennium Management
Millennium Management
New York
+$36.5M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$36M
5
Franklin Resources
Franklin Resources
California
+$24M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$34.3M
2
NLVP
New Leaf Venture Partners
New York
-$30.5M
3
EA
Emerald Advisers
Pennsylvania
-$11.6M
4
SHI
SV Health Investors
Massachusetts
-$11.1M
5
EP
Eversept Partners
New York
-$8.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
Swiss National Bank
51
Swiss National Bank
Switzerland
$1.55M +$625K +21,100 +86%
GPCM
52
Granite Point Capital Management
Massachusetts
$1.43M +$1.24M +42,000 New
PVI
53
Pura Vida Investments
New York
$1.39M +$1.21M +41,000 New
Two Sigma Investments
54
Two Sigma Investments
New York
$1.39M +$1.21M +41,021 New
Rafferty Asset Management
55
Rafferty Asset Management
New York
$1.35M +$275K +9,293 +30%
ACA
56
Apis Capital Advisors
New York
$1.32M +$1.15M +39,000 New
NCM
57
Nantahala Capital Management
Connecticut
$1.3M +$1.13M +38,247 New
Susquehanna International Group
58
Susquehanna International Group
Pennsylvania
$1.28M +$699K +23,621 +166%
D.E. Shaw & Co
59
D.E. Shaw & Co
New York
$1.28M +$1.12M +37,689 New
Victory Capital Management
60
Victory Capital Management
Texas
$1.19M +$1.02M +34,463 +4,868%
OAM
61
Oxford Asset Management
United Kingdom
$1.17M +$1.02M +34,545 New
Barclays
62
Barclays
United Kingdom
$1.14M +$709K +23,967 +250%
Man Group
63
Man Group
United Kingdom
$1.08M +$941K +31,800 New
California State Teachers Retirement System (CalSTRS)
64
California State Teachers Retirement System (CalSTRS)
California
$1M +$201K +6,805 +30%
Voloridge Investment Management
65
Voloridge Investment Management
Florida
$973K +$848K +28,654 New
PPA
66
Parametric Portfolio Associates
Washington
$898K +$7.02K +237 +0.9%
Invesco
67
Invesco
Georgia
$803K +$701K +23,671 New
LI
68
Leap Investments
Illinois
$801K +$699K +23,600 New
Citigroup
69
Citigroup
New York
$798K -$377K -12,721 -35%
RhumbLine Advisers
70
RhumbLine Advisers
Massachusetts
$763K +$185K +6,245 +38%
State of Wisconsin Investment Board
71
State of Wisconsin Investment Board
Wisconsin
$750K +$299K +10,100 +84%
EP
72
Eversept Partners
New York
$747K -$8.38M -283,233 -93%
SIM
73
Spark Investment Management
New York
$695K +$255K +8,600 +72%
DCM
74
Driehaus Capital Management
Illinois
$679K +$592K +20,000 New
QI
75
QS Investors
New York
$676K – – –
1 2
3
4 5

DCPH Hedge Fund Activity: Q3 2019 in Review

122 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q3 2019, worth a combined $1.2B — up 130% from $522M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new DCPH positions and 10 closed out — a net gain of 37 holders — while 49 added to existing stakes and 19 trimmed.

The largest buyer was Redmile Group, adding an estimated $75.7M. The largest seller was OrbiMed, cutting an estimated $34.3M.

  • 122 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q3 2019, up from 85 in Q2 2019.
  • Funds reported $1.2B of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q3 2019, up 130% quarter-over-quarter.
  • 47 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q3 2019 and 10 closed out, a net change of +37 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q3 2019 was Redmile Group, an estimated $75.7M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q3 2019 was OrbiMed, an estimated $34.3M sold.

Based on aggregated 13F filings for Q3 2019.